Form 4: KALA BIO Director Marjan Farid Receives Significant Equity Grants

KALA BIO, Inc. Director Marjan Farid was granted 2,450 restricted stock units and options to purchase 5,450 shares of common stock on June 15, 2025, as part of the company's equity incentive plan.

Summary

• Marjan Farid, a Director of KALA BIO, Inc. (KALA), received equity grants on June 15, 2025.
• The grants include 2,450 Restricted Stock Units (RSUs) and stock options for 5,450 shares of common stock.
• The RSUs were granted at a price of $0, and the stock options have an exercise price of $4.3 per share, also granted at a price of $0.
• Both the RSUs and stock options will vest 100% on the earlier of June 15, 2026, or the date of the first annual meeting of stockholders occurring in 2026.
• Following these transactions, Marjan Farid beneficially owns 10,242 shares of common stock, which includes 5,134 unvested RSUs.
• Marjan Farid also beneficially owns 5,450 stock options, which expire on June 14, 2035.

Sentiment

Score: 7

Explanation: The filing indicates a routine equity grant to a director, which is a positive for aligning management interests with shareholders and is a standard compensation practice. It does not contain any negative financial news or unexpected events.

Positives

• The grant of equity to a director aligns their financial interests with those of the company's shareholders, promoting long-term value creation.
• The grants are made under the Issuer's Amended and Restated 2017 Equity Incentive Plan, indicating a structured and established approach to executive and director compensation.

Risks

• The vesting of both the Restricted Stock Units and stock options is contingent upon the reporting person's continued service to the company, meaning the equity could be forfeited if service ceases before the vesting date.

Future Outlook

The equity grants are designed to incentivize the director's continued service and align their interests with the company's long-term performance, with vesting contingent on service through mid-2026 or the 2026 annual meeting.

Industry Context

Equity grants to directors and executives are a standard compensation practice across publicly traded companies, particularly in the biotechnology sector, to attract, retain, and incentivize key personnel by aligning their financial success with shareholder value creation.

Comparison to Industry Standards

• Equity-based compensation, such as Restricted Stock Units and stock options, is a common and widely accepted practice for compensating directors in publicly traded companies, including those in the biotech industry like KALA BIO.
• The specific size of the grant (2,450 RSUs and 5,450 options) and the exercise price ($4.3) would typically be benchmarked against director compensation packages at peer companies within the biotechnology sector to assess competitiveness and alignment with industry norms. This document does not provide such comparative data.

Corporate Governance

Related Party Transactions

• Grant of 2,450 Restricted Stock Units and options to purchase 5,450 shares of common stock to Marjan Farid, a Director of KALA BIO, Inc., as part of the company's equity incentive plan. This is a transaction between the company and a related party (director).

Stakeholder Impact

• Shareholders: The equity grants further align the interests of a key director with those of the shareholders, potentially leading to more focused efforts on long-term company performance and value creation.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The director's continued service is required for the vesting of the granted Restricted Stock Units and stock options.
• The RSUs and stock options are scheduled to vest on the earlier of June 15, 2026, or the date of the first annual meeting of stockholders in 2026.
• The director has the potential to exercise the stock options at any point after vesting and before their expiration on June 14, 2035.

Key Dates

Keywords

KALA BIO, KALA, Marjan Farid, Director, SEC Form 4, Equity Grant, Restricted Stock Units, Stock Options, Insider Transaction, Compensation, Corporate Governance